BEAT-MRT - Base editing against cancer – a gene correction strategy for rhabdoid tumours
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Malignant rhabdoid tumours (MRTs) are among the most aggressive paediatric cancers, with overall survival rates below 30%. The genetic hallmark of MRTs is the biallelic inactivation of SMARCB1 (or, rarely, SMARCA4). This single-driver, loss-of-function alteration disrupts...